1. Home
  2. RPRX vs PFG Comparison

RPRX vs PFG Comparison

Compare RPRX & PFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • PFG
  • Stock Information
  • Founded
  • RPRX 1996
  • PFG 1879
  • Country
  • RPRX United States
  • PFG United States
  • Employees
  • RPRX N/A
  • PFG N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • PFG Specialty Insurers
  • Sector
  • RPRX Health Care
  • PFG Finance
  • Exchange
  • RPRX Nasdaq
  • PFG Nasdaq
  • Market Cap
  • RPRX 14.2B
  • PFG 16.3B
  • IPO Year
  • RPRX 2020
  • PFG N/A
  • Fundamental
  • Price
  • RPRX $32.20
  • PFG $73.46
  • Analyst Decision
  • RPRX Strong Buy
  • PFG Hold
  • Analyst Count
  • RPRX 4
  • PFG 14
  • Target Price
  • RPRX $42.50
  • PFG $84.71
  • AVG Volume (30 Days)
  • RPRX 4.5M
  • PFG 1.9M
  • Earning Date
  • RPRX 05-08-2025
  • PFG 04-24-2025
  • Dividend Yield
  • RPRX 2.73%
  • PFG 3.96%
  • EPS Growth
  • RPRX N/A
  • PFG N/A
  • EPS
  • RPRX 1.91
  • PFG N/A
  • Revenue
  • RPRX $2,263,576,000.00
  • PFG $16,127,700,000.00
  • Revenue This Year
  • RPRX $31.56
  • PFG $0.78
  • Revenue Next Year
  • RPRX $5.94
  • PFG $4.32
  • P/E Ratio
  • RPRX $16.84
  • PFG $10.63
  • Revenue Growth
  • RPRX N/A
  • PFG 18.02
  • 52 Week Low
  • RPRX $24.05
  • PFG $68.39
  • 52 Week High
  • RPRX $34.20
  • PFG $91.98
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 51.13
  • PFG 43.36
  • Support Level
  • RPRX $31.58
  • PFG $69.80
  • Resistance Level
  • RPRX $32.73
  • PFG $76.13
  • Average True Range (ATR)
  • RPRX 0.93
  • PFG 3.29
  • MACD
  • RPRX 0.06
  • PFG 0.28
  • Stochastic Oscillator
  • RPRX 82.74
  • PFG 53.88

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About PFG Principal Financial Group Inc

Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.

Share on Social Networks: